Different characteristics of non culprit plaque by OCT

Original title: Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: A 3-vessel optical coherence tomography study. Reference: Rocco Vergallo et al. Am Heart J 2014;167:59-67.

Recent studies have described different clinical characteristics between ACS patients with and without ruptured culprit plaque. Given the systemic nature of atherosclerosis, the hypothesis of this study is that non culprit lesions would also express different characteristics than culprit lesions.

Based on culprit lesion characteristics, the population was divided in two groups: patients with ruptured plaque at the culprit lesion and patients with non ruptured plaque at the culprit lesion. Prevalence and characteristics of non culprit plaques were compared between these two groups of patients.

118 non culprit lesions were analyzed. Patients in the group with ruptured culprit lesion (n=17) presented non culprit plaque with higher prevalence of fibroatheroma with thin cap (52.9% vs 19.0%; p=0.029) or ruptured (35.3% vs 4.8%; p=0.016) compared to those patients whose culprit lesion was not ruptured (n=21).

In absolute values, the cap of non culprit lesions in the first group measured 107.0 ± 56.5 μm vs 137.3 ± 69.8 μm in the second group, a difference that turned out significative (p=0.035). All lipid content measurement parameters resulted higher in the non culprit plaque patients than in the group of ruptured culprit lesions.

Conclusion

The present study showed different characteristics of non culprit lesions by OCT between those patients presenting ACS caused by ruptured plaques and those whose culprit lesions were not ruptured.

Editorial Comment

This study has the limitation of being retrospective from the Massachusetts General Hospital OCT registry. The use of OCT in the 3 coronary vessels could have been limited by the context of ACS given the its clinically unstable nature and the difficulty to assess distal or ostial lesions. 

SOLACI

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...